These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35287311)

  • 41. Efficacy and safety of molnupiravir for COVID-19 patients.
    Fatima M; Azeem S; Saeed J; Shahid A; Cheema HA;
    Eur J Intern Med; 2022 Aug; 102():118-121. PubMed ID: 35649740
    [No Abstract]   [Full Text] [Related]  

  • 42. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
    Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis.
    Lawrence JM; Mirchandani M; Hill A
    J Antimicrob Chemother; 2023 Mar; 78(3):613-619. PubMed ID: 36611248
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis.
    Chang YC; Chen YC; Huang CC; Fu CM; Lee YT; Wu PJ; Lee WC; Lee CT; Liao SC; Tsai KF
    Int J Antimicrob Agents; 2023 Jul; 62(1):106834. PubMed ID: 37127127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro.
    Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Comez L; Libera V; Macchiarulo A; Paciaroni A; Vicenti I; Zazzi M; Francisci D
    Microorganisms; 2022 Jul; 10(7):. PubMed ID: 35889194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative evaluation of authorized drugs for treating Covid-19 patients.
    Islam T; Hasan M; Rahman MS; Islam MR
    Health Sci Rep; 2022 Jul; 5(4):e671. PubMed ID: 35734340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing hospitalization.
    Scioscia G; De Pace CC; Giganti G; Tondo P; Foschino Barbaro MP; Lacedonia D
    Ir J Med Sci; 2023 Oct; 192(5):2301-2303. PubMed ID: 36454535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insight into the biological impact of COVID-19 and its vaccines on human health.
    Ashwlayan VD; Antlash C; Imran M; Asdaq SMB; Alshammari MK; Alomani M; Alzahrani E; Sharma D; Tomar R; Arora MK
    Saudi J Biol Sci; 2022 May; 29(5):3326-3337. PubMed ID: 35185356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Umifenovir and coronavirus infections: a review of research results and clinical practice].
    Leneva IA; Pshenichnaya NY; Bulgakova VA
    Ter Arkh; 2020 Dec; 92(11):91-97. PubMed ID: 33720612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review on molnupiravir as a promising oral drug for the treatment of COVID-19.
    Zarenezhad E; Marzi M
    Med Chem Res; 2022; 31(2):232-243. PubMed ID: 35002192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    bioRxiv; 2022 Feb; ():. PubMed ID: 35233571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting-A Single Center Experience.
    Czarnecka K; Czarnecka P; Tronina O; Durlik M
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molnupiravir as an Early Treatment for COVID-19: A Real Life Study.
    Pontolillo M; Ucciferri C; Borrelli P; Di Nicola M; Vecchiet J; Falasca K
    Pathogens; 2022 Sep; 11(10):. PubMed ID: 36297178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.
    Stegmann KM; Dickmanns A; Heinen N; Blaurock C; Karrasch T; Breithaupt A; Klopfleisch R; Uhlig N; Eberlein V; Issmail L; Herrmann ST; Schreieck A; Peelen E; Kohlhof H; Sadeghi B; Riek A; Speakman JR; Groß U; Görlich D; Vitt D; Müller T; Grunwald T; Pfaender S; Balkema-Buschmann A; Dobbelstein M
    iScience; 2022 May; 25(5):104293. PubMed ID: 35492218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Use of Molnupiravir in the Treatment of Outpatients with SARS-CoV-2 Infection-A Patient Profile Based on the Experience of a Tertiary Infectious Disease Center.
    Streinu-Cercel A; Miron VD; Oană AA; Irimia M; Popescu RȘ; Dărămuș IA; Moțoi MM; Ceapraga GJ; Săndulescu O
    Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry.
    Lupia T; Corcione S; Shbaklo N; Boglione L; Torresan S; Pinna SM; Rizzello B; Bosio R; Fornari V; Brusa MT; Borrè S; De Rosa FG
    Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36358196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molnupiravir, favipiravir and other antiviral drugs with proposed potentials for management of COVID-19: a concern on antioxidant aspect.
    Yasri S; Wiwanitki V
    Int J Biochem Mol Biol; 2022; 13(1):1-4. PubMed ID: 35295914
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molnupiravir is effective in patients with haematological malignancies.
    Bołkun Ł; Pula B; Kołkowska-Leśniak A; Morawska M; Cichocka E; Charlinski G; Garus B; Giebel S; Piszcz J; Drozd-Sokolowska J; Kwiatkowski J; Biernat M; Hus I; Lech-Maranda E; Długosz-Danecka M; Giannopoulos K; Wróbel T
    Int J Cancer; 2023 Sep; 153(6):1251-1256. PubMed ID: 36691818
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.